Literature DB >> 26313523

Clinical significance of D4A in prostate cancer therapy with abiraterone.

Hamid Emamekhoo1, Zhenfei Li2, Nima Sharifi1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26313523      PMCID： PMC4825540          DOI： 10.1080/15384101.2015.1086201

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.

Authors:  Kai-Hsiung Chang; Rui Li; Barbara Kuri; Yair Lotan; Claus G Roehrborn; Jiayan Liu; Robert Vessella; Peter S Nelson; Payal Kapur; Xiaofeng Guo; Hamid Mirzaei; Richard J Auchus; Nima Sharifi
Journal:  Cell       Date:  2013-08-29       Impact factor: 41.582

2.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

3.  Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.

Authors:  Arun A Azad; Bernhard J Eigl; R Nevin Murray; Christian Kollmannsberger; Kim N Chi
Journal:  Eur Urol       Date:  2014-07-10       Impact factor: 20.096

4.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245

5.  Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Authors:  Juliet Richards; Ai Chiin Lim; Colin W Hay; Angela E Taylor; Anna Wingate; Karolina Nowakowska; Carmel Pezaro; Suzanne Carreira; Jane Goodall; Wiebke Arlt; Iain J McEwan; Johann S de Bono; Gerhardt Attard
Journal:  Cancer Res       Date:  2012-03-12       Impact factor: 12.701

6.  Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer.

Authors:  Zhenfei Li; Andrew C Bishop; Mohammad Alyamani; Jorge A Garcia; Robert Dreicer; Dustin Bunch; Jiayan Liu; Sunil K Upadhyay; Richard J Auchus; Nima Sharifi
Journal:  Nature       Date:  2015-06-01       Impact factor: 49.962
  6 in total
  1 in total

1.  Author's Reply to Srinivas: "Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".

Authors:  Steven Xu; Peter De Porre
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.